Atorvastatin
1. Pregnancy Evidence & Regulatory Labeling
FDA Pregnancy and Lactation Labeling Rule (PLLR 8.1) & EMA SmPC Section 4.6
Clinical Risk Summary
Contraindicated / Discontinue in Pregnancy. Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including steroidogenesis and cell membrane formation). Discontinue atorvastatin when pregnancy is recognized, as the treatment of hyperlipidemia is not typically urgent during pregnancy.
Human Pregnancy Experience & Clinical Studies
Prospective observational registries show limited human teratogenicity signal; however, theoretical disruption of embryogenesis justifies discontinuation.
Animal Reproductive & Developmental Toxicity Data
High doses in rats produced decreased fetal body weight, delayed skeletal ossification, and neonatal pup mortality.
Clinical Considerations for Prescribers
Discontinue immediately prior to planned conception or as soon as pregnancy is recognized. In patients with homozygous familial hypercholesterolemia, individualized specialist consultation is required.
Placental Transfer
Lipophilic molecule with documented placental penetration.
Regulatory Warnings & Contraindications
Contraindicated during pregnancy due to suppression of essential fetal cholesterol synthesis.
2. Lactation & Breastfeeding Safety
NIH / NLM LactMed® Database & FDA Labeling Section 8.2
Summary of Use during Lactation
Breastfeeding is not recommended during atorvastatin therapy due to the potential for adverse effects on infant lipid metabolism and cellular development.
Drug Levels in Breast Milk & Relative Infant Dose
Present in rat milk; human breast milk excretion is probable given lipophilicity.
Effects in Breastfed Infants & Monitored Signs
Theoretical risk of disruption of infant central nervous system myelination and lipid homeostasis.
Effects on Lactation & Milk Production
No known impact on milk production.
Alternate Medications with Established Lactation Data
4. Regulatory Source Provenance & Comparison
Direct attribution to official regulatory documents without synthesized consensus
| Regulatory Organization | Jurisdiction | Document / Framework | Effective Date | Official Source Link |
|---|---|---|---|---|
|
U.S. Food and Drug Administration (FDA)
FDA Prescribing Information (PLLR)
|
United States | regulatory_label | 2026-07-01 | Official Record |
|
National Institutes of Health (NIH) / NLM
LactMed® Database (Drugs and Lactation)
|
United States / Global | evidence_monograph | 2026-08-01 | Official Record |